Skip to main content
HCPCS J9000 · Level II · Part B drug

J9000: doxorubicin hydrochloride (Adriamycin), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9000

Billing unit
10 MG
Doxorubicin hcl injection
ASP payment limit
$3.12
October 2026; +15.1% vs July 2026
Practitioner MUE
20
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9000 is the Level II code for Injection, doxorubicin hydrochloride, 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $3.12 per billing unit, up 15.1% from July 2026. The practitioner MUE allows up to 20 units per date of service (MAI 3), so a full 20-unit day is $62.40 at the current limit. Under OPPS it carries status indicator N. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. Other HCPCS codes whose descriptor names doxorubicin hydrochloride: Q2050 (not otherwise specified (for products without their own code); liposomal); Q2049 (CMS descriptor names "imported lipodox"; liposomal; billed per 10 mg). The ASP crosswalk maps 42 NDCs to it, sold as Doxorubicin HCl, Adriamycin by Pfizer Inc, Hikma Pharmaceuticals USA Inc., Sagent Pharmaceuticals. No current Billing and Coding Article lists J9000, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9000 at $3.12 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $2.71 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9000
QuarterPayment limitPerCoinsurance
October 2026$3.1210 MG20%
July 2026$2.7110 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 42 NDCs from 7 labelers to J9000. Report the NDC in the claim's drug segment and bill the number of J9000 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to J9000
NDCDrug nameLabelerPackage sizeBilling units / package
00069-0255-10Doxorubicin HClPfizer Inc10 × 12
00069-0277-02Doxorubicin HClPfizer Inc10 × 12
00069-0343-02Doxorubicin HClPfizer Inc25 × 15
00069-0358-20Doxorubicin HClPfizer Inc5 × 11
00069-1442-04Doxorubicin HClPfizer Inc100 × 120
00069-1542-20Doxorubicin HClPfizer Inc100 × 120
00069-3030-20Doxorubicin HClPfizer Inc5 × 11
00069-3031-20Doxorubicin HClPfizer Inc10 × 12
00069-3032-20Doxorubicin HClPfizer Inc25 × 15
00069-3034-20Doxorubicin HClPfizer Inc100 × 120
00069-3358-25Doxorubicin HClPfizer Inc25 × 15
00069-4004-05Doxorubicin HClPfizer Inc5 × 11
00069-4015-10Doxorubicin HClPfizer Inc10 × 12
00069-4026-25Doxorubicin HClPfizer Inc25 × 15
00069-4031-12Doxorubicin HClPfizer Inc10 × 12
00069-4037-01Doxorubicin HClPfizer Inc100 × 120
00069-4205-05Doxorubicin HClPfizer Inc5 × 11
00069-5629-05Doxorubicin HClPfizer Inc5 × 11
00143-9084-01Doxorubicin HClHikma Pharmaceuticals USA Inc.5 × 11
00143-9085-01Doxorubicin HClHikma Pharmaceuticals USA Inc.10 × 12
00143-9086-01Doxorubicin HClHikma Pharmaceuticals USA Inc.25 × 15
00143-9087-01Doxorubicin HClHikma Pharmaceuticals USA Inc.100 × 120
00143-9088-01Doxorubicin HClHikma Pharmaceuticals USA Inc.5 × 11
00143-9089-01Doxorubicin HClHikma Pharmaceuticals USA Inc.10 × 12
00143-9090-01Doxorubicin HClHikma Pharmaceuticals USA Inc.25 × 15
00143-9091-01Doxorubicin HClHikma Pharmaceuticals USA Inc.100 × 120
00143-9092-01Doxorubicin HClHikma Pharmaceuticals USA Inc.5 × 11
00143-9093-01Doxorubicin HClHikma Pharmaceuticals USA Inc.1 × 15
00143-9277-01AdriamycinHikma Pharmaceuticals USA Inc.1 × 15
25021-0207-05Doxorubicin HClSagent Pharmaceuticals5 × 1010
25021-0207-25Doxorubicin HClSagent Pharmaceuticals25 × 15
25021-0207-51Doxorubicin HClSagent Pharmaceuticals100 × 120
45963-0733-55Doxorubicin HClActavis Pharma, Inc.5 × 11
45963-0733-57Doxorubicin HClActavis Pharma, Inc.10 × 12
45963-0733-60Doxorubicin HClActavis Pharma, Inc.100 × 120
45963-0733-68Doxorubicin HClActavis Pharma, Inc.25 × 15
63323-0101-61Doxorubicin HClFreseniUS Kabi USA, LLC100 × 120
63323-0883-05Doxorubicin HClFreseniUS Kabi USA, LLC5 × 11
63323-0883-30Doxorubicin HClFreseniUS Kabi USA, LLC25 × 15
67457-0436-50Doxorubicin HClMylan Institutional LLC1 × 15
70860-0208-25Doxorubicin HClAthenex Pharmaceutical Division, LLC25 × 15
70860-0208-51Doxorubicin HClAthenex Pharmaceutical Division, LLC100 × 120

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9000. For practitioners the limit is 20 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9000 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services203 Date of Service Edit: ClinicalClinical: Data
Facility outpatient hospital203 Date of Service Edit: ClinicalClinical: Data
DME supplier203 Date of Service Edit: ClinicalClinical: Data

MUE for J9000 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9000 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9000 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9000 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9000 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Local coverage policies that list J9000

1 active Local Coverage Determination lists J9000 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9000 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9000 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J9000 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9000

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9000

What does HCPCS code J9000 describe?

J9000 is defined by CMS as "Injection, doxorubicin hydrochloride, 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9000 a CPT code?

No. J9000 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as doxorubicin hydrochloride (Adriamycin); CPT codes are five-character codes maintained by the AMA. On a Part B claim J9000 reports the drug itself in 10 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9000 in October 2026?

The ASP-based payment limit is $3.12 per 10 MG, with 20% beneficiary coinsurance. The July 2026 limit was $2.71. Commercial payers use their own fee schedules.

How many units of J9000 can be billed per day?

The practitioner Medically Unlikely Edit is 20 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: Data" as the rationale.

Which NDCs map to J9000?

The October 2026 ASP crosswalk lists 42 NDCs from 7 labelers: Doxorubicin HCl (Pfizer Inc); Doxorubicin HCl (Hikma Pharmaceuticals USA Inc.); Adriamycin (Hikma Pharmaceuticals USA Inc.); Doxorubicin HCl (Sagent Pharmaceuticals). For example NDC 00069-0255-10 (package size 10) equals 2 billing units of J9000.

Does J9000 have NCCI bundling edits?

No active practitioner PTP pairs list J9000 as a column-1 or column-2 code in the v323r0 release.

J9000 vs Q2050: what is the difference?

Both are HCPCS Level II codes whose descriptor names doxorubicin hydrochloride. What sets Q2050 apart: not otherwise specified (for products without their own code); liposomal. J9000 is billed per 10 mg, limit $3.12, MUE 20; Q2050 is billed per 10 mg, limit $97.823, MUE 14. Report the code whose descriptor matches the product and setting in the record.

J9000 vs Q2049: what is the difference?

Both are HCPCS Level II codes whose descriptor names doxorubicin hydrochloride. What sets Q2049 apart: CMS descriptor names "imported lipodox"; liposomal; billed per 10 mg. J9000 is billed per 10 mg, limit $3.12, MUE 20; Q2049 is billed per 10 mg, OPPS rate $298.74, MUE 10. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.